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ABSTRACT
Doxorubicin (Dox) is a potent chemotherapeutic drug used for the treatment of
various cancers. Unfortunately, its use is limited as Dox induces adverse cardiotoxicity
(DIC) and muscle toxicity (DIMT), which are mediated through oxidative stress, ER stress,
and inflammation. However, it remains unknown whether Dox induces an inflammation
mediated cell death, called “pyroptosis”. The current study is designed to determine
whether Dox induces pyroptosis in cardiac and muscle cell culture models. Moreover,
the protective effects of embryonic stem cell-derived exosomes (ES-Exos) in inhibiting
pyroptosis will also be determined. For this purpose, we designed two different cell culture
models using H9c2 cadiomyoblasts and Sol 8 cells. For the DIC model, H9c2 were
exposed to Dox to induce pyroptosis and then treated with exosomes. Cells were divided
into 4 groups: Control, Dox, Dox+ES-Exos, and Dox+MEF-Exos (negative control).
Furthermore, to generate the DIMT model, Sol 8 cells were incubated with Dox+THP-1
conditioned medium (TCM) to induce toxicity and inflammation, which was followed by
exosomes treatment. We assigned cells into 5 groups: Control, Dox+TCM,
Dox+TCM+ES-Exos, Dox+TCM+MEF-Exos (negative control), and Dox+TCM+ESExos+GW4869 compound (exosomes inhibitor, negative control). Our data shows that
Dox treatment significantly increased pyroptotic marker expression including TLR-4,
NLRP3, caspase-1, IL1-β, Caspase-11, and gasdermin-D as well as increased proinflammatory TNF-α and IL-6 expression in H9c2 cells. There was also a significant
increase in caspase-1, IL1-β, and IL-18 expression in Dox+TCM treated Sol 8 cells.
Conversely, increased pyroptosis and inflammation post-Dox treatment were inhibited by
ES-Exos in both culture models. No significant changes observed upon MEF-Exos and
iii

GW4869 compound treatments. In conclusion, our data shows Dox induces pyroptosis
and inflammation within cardiac and skeletal muscle cells, which can be inhibited
following treatment with ES-exosomes. This is a novel study with new mechanistic
observations on the pathophysiological role of pyroptosis in Dox-induced cardio and
muscle toxicities.
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CHAPTER 1: INTRODUCTION
Cancer Treatment with Doxorubicin
The anthracycline family originated more than 60 years ago (1950’s) with the
exploration of Daunorubicin, which was found to be applicable and efficient in treating
lymphomas and leukemias (63).

After few years, a new Daunorubicin derivative,

Adriamycin (name changed to doxorubicin later), was identified and demonstrated as
more effective anti-cancer agent (63). Anthracycline chemotherapeutic drugs such as
doxorubicin administered for treating a wide variety of hematologic malignancies and solid
organ tumors, such as lymphoma, leukemia, lung, and breast cancer (14; 60). However,
reported evidences indicate their effectiveness in cancer therapy is restricted by an acute,
dose-dependent toxicity within the heart and skeletal muscles (cardiotoxicity and muscle
toxicity), which can cause irreversible cardiac and muscular dysfunction (7; 39; 62). Doxbased chemotherapy manifests cardiotoxicities including autonomic cardiovascular
dysfunction, myocardial infarction (MI), and heart failure. Muscle toxicity induced by Dox
appears as muscle fatigue, weakness, and dysfunction.
Prevalence of Toxicity upon Dox Administration
Previous studies have been performed to measure alteration in left ventricular
ejection fraction (LVEF) through chemotherapy using anthracyclines, and confirmed a
dose-dependent reduction in LVEF (31; 66). Analysis of breast cancer and lung tumor
treated with Dox, along with measuring LVEF using equilibrium radionuclide angiography
(ERNA), revealed that about 5% of patients demonstrated signs of congestive heart
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failure or a notable diminishment in left ventricular function, as well as dose-dependent
cardiotoxicity (36). Recent studies indicate that more than 60 percent of patients that have
a childhood cancer and are treated with Dox, show LV contractile abnormalities in their
echocardiographic evaluation (29; 43; 63).
Additionally, clinical reports have shown dose-dependent muscle toxicity with Dox
treatment. According to these studies, patients with advanced cancer show a reduction
in muscle strength in their extremities compared to the control patients, and also develop
impaired physical performance with Doxorubicin treatment. This muscular dysfunction is
usually related to muscle mass reduction (atrophy), chronic muscle fatigue, weakness,
inflammation, and cell death within muscles (15; 62).
Toxicity Pathophysiology
While the primary mechanism of action of Doxorubicin for killing uncontrolled
dividing cancerous cells is related to DNA damage via disruption of the cell cycle, the
toxicity that Dox exhibits in cardiac and muscle cells is mainly related to free radicals
formed from its metabolism. Subsequently, these free radicals result in production of
reactive oxygen species (ROS). ROS produced in cardiomyocytes and muscle cells
cause cell death through necrosis (cell swelling in response to external factos, which
causes organelle and DNA damages, membrane rupture, and uncontrolled inflammatory
responses) and apoptosis (via cytochrome C secretion from mitochondria, which results
in activation of the apoptosome and caspase-9/3) (25; 26; 63). The current study is
undertaken to establish whether Dox induces a new type of programmed inflammatorymediated cell death known as pyroptosis. Pyroptosis occurs via stimulation of the TLR4
2

receptor that produces the NLRP3 inflammasome due to released damage-associated
molecular patterns (DAMPs) in the disease condition. In the next step, the inflammasome
activates caspase-1, which causes the release of cytokines IL-1β and IL-18, and leads to
pore formation within the cell membrane via stimulation of caspase-11 and gesdermin-D
resulting in secretion of pro-inflammatory cytokines from the dead cell (11; 18; 34).
Stem Cells Therapy for Cardiac and Muscle Toxicity
Scientists have explored that cell-based therapy could be applied as a potential
therapeutic approach that is able to mitigate cell death consequent to various
cardio/muscle toxicity manifestations (8; 47). Candidate cell types that have been used
for transplantation in cardiovascular disorders (CVDs) and muscle diseases include
mesenchymal stem cells, myoblast cells, induced pluripotent stem (iPS) cells, embryonic
stem cells (ES cells), bone marrow cells, and hematopoietic stem cells (51). ES cells
possess many desirable characteristics including self-renewal ability (plasticity) and
pluripotency, which introduce this cell line an ideal option for use in cardiotoxicity and
muscle toxicity resulting from Dox administration (49; 55). ES cells are derived from the
inner cell mass (ICM) of the blastocyst, and are pluripotent, undifferentiated cells that
enable them to differentiate to any cell types arising from the 3 different germ layers
(endoderm, mesoderm and ectoderm) (52). Previous studies have revealed that
transplanted ES cells are able to differentiate and generate all 3 types of cardiac cell
lineages including cardiomyocytes (CMs), endothelial cells (ECs), and vascular smooth
muscle cells (VSMCs), as well as formation of skeletal muscle cells within the body (49;
52; 62). Therefore, transplanted ES cells are able to reduce adverse cardiac and muscle
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remodeling. However, this therapeutic approach has faced with some challenges; the
main one being increased risk of teratoma formation (tumorigenesis) due to pluripotency
(16; 19; 38).
Exosomes
Exosomes (Exos) are 30-100 nm diameter vesicles secreted by the cell through
exocytosis. Multi-vesicular bodies (MVBs) form within the cell and pack cell contents as
exosomal vesicles and carrying the cell’s components including proteins, lipids, factors,
and genetic materials, specifically miRNAs and mRNAs (5; 12). These vesicles
communicate with the target cells via cargo transportation. Based on current studies, ES
cell- derived exosomes (ES-Exos) contain all growth factors, cell protective components,
and micro-RNAs present within ES cells (51). Therefore, these cell-free therapeutic
agents are expected to be as effective as ES cells, play a role in preventing apoptosis
and fibrosis, and improving angiogenesis (51; 56; 62). Thus, we assume exosomes are
involved in protection, repair, and regeneration upon injuries. However, ES-Exos effect
on prevention or inhibition of pyroptosis within the heart and skeletal muscles is still
unknown. In addition to ES cells, we isolated Exos from mouse embryonic fibroblasts
(MEF). Fibroblasts are matured cells that mainly maintain structural integrity of connective
tissues. Thus, MEF-Exos were administered as a negative control in this research study,
and we did not expect to see significant changes upon MEF-Exo treatment.
Rational and Aims
Pyroptotic cell death caused by Dox is thought to be the leading cause of cardiac
and muscle toxicities. Additionally, conventional medical alternatives have not been
4

wholly successful in either cardiac or muscle recovery. For example, organ/tissue
transplantation is limited due to limited donor supply, high cost, ethical issues, and
necessity for immunosuppressant remedies (2; 17; 65). In last few decades, exhaustive
efforts have been put into the improvement of cell transplantation approach to establish
an efficient treatment for different toxicity manifestations induced by Dox (52; 53). Recent
experiments indicate transplanted ES cells in the injured heart or muscle could
differentiate into new healthy cells and hinder adverse remodeling (apoptosis, necrosis,
fibrosis, and hypertrophy); however, the efficacy of these transplanted ES cells in
attenuation of adverse remodeling is limited (52; 53). Although, the major restrictive side
effect of this therapeutic strategy known as teratoma (16). Therefore, many studies have
focused on replacing it with a safer alternate approach that could be as efficient as ES
cell therapy, but relieves the major challenge: teratoma formation.
The current study was pursued with two major goals. The first aim was to assess
interventions of derived exosomes from ES cells to reduce Dox-induced pyroptosis in
H9c2 cells. We hypothesized that Dox induces cardiotoxicity via stimulation of
inflammatory-mediated pyroptotic cell death within the heart, and that ES-Exos could
attenuate this pyroptosis.
In addition, we hypothesized that Dox induces muscle-toxicity through induction of
pyroptosis in soleus muscle cells (Sol 8 cells), which is inhibited via ES-Exos treatment.
Respectively, the second goal was to identify the therapeutic effect of ES-Exos on
reduction of Dox-induced pyroptosis in the Sol 8 cell line.
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Figure 1. Doxorubicin Induces Pyroptosis.
Released DAMPs (HMGB1 and HSP) from dead cells have a great potential to bind and
activate the TLR-4 receptor on the membrane of cardiac and muscle cells. Stimulation of
TLR-4 would follow with formation of the NLRP3 inflammasome and induction of caspase1. Caspase-1 stimulates caspase-11 and gasdermin-D proteins, which are involved in
pore formation in the cell membrane. Caspase-1 also triggers IL-1β and IL-18 cytokines
to be secreted from the dead cell.
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CHAPTER 2: EMBRYONIC STEM CELL-DERIVED EXOSOMES INHIBIT
DOXORUBICIN-INDUCED PYROPTOSIS IN CARDIAC CELLS

Abstract
Doxorubicin (Dox) is an effective anti-tumor agent that believed to cause
cardiotoxicity as the major side effect due to increased oxidative stress, endoplasmic
reticulum (ER) stress, and inflammation. However, it remains unidentified whether Dox
induces an inflammatory-mediated form of cell death called “pyroptosis” inside the heart.
The current study is undertaken to determine whether Dox induces pyroptosis in an in
vitro model, and to clarify the capacity of exosomal vesicles-derived from embryonic stem
cells (ES-Exos) in inhibiting pyroptosis. For this purpose, H9c2 rat cardiomyoblast cells
were exposed to Dox to generate pyroptosis and subsequently treated with exosomes to
investigate the protective effects of these therapeutic agents. MEF-exosomes used as a
negative control. Pyroptosis was confirmed through immunocytochemistry and western
blot methodologies using pyroptotic markers: TLR-4, NLRP3, caspase-1, IL-1β, caspase11, and gasdermin-D. Further, inflammation was analyzed via western blot and ELISA of
inflammatory cytokines TNF-α and IL-6. Our data shows that Dox exposure significantly
increases expression of TLR-4, NLRP3, caspase-1, IL-1β, caspase-11, gasdermin-D, and
pro-inflammatory cytokines TNF-α and IL-6. This increased pyroptosis and inflammation
was diminished by ES-Exos treatment; but no notable changes were observed upon
treatment with MEF-exosomes. In conclusion, these results indicate that Dox causes
inflammatory pyroptotic cell death in the cardiac cell culture model (H9c2 cells), which
was subsequently inhibited with ES-Exos treatment.
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Introduction
Doxorubicin (Dox) is a chemotherapeutic agent with anti-cancer activity against a
broad diversity of cancers such as leukemia, lymphoma, lung, and breast cancer. Dox
functions to disrupt the cell cycle, which stimulates cancerous cell death; however, it can
cause unwanted cell death in other healthy tissues, resulting in serious adverse effects
(14). Administration of Dox has been restricted in use due to acute dose-dependent
cardiotoxicity that may generate cardiac cell death, leading to cardiomyopathy and
eventually heart failure (69). Dox-induced cardiotoxicity (DIC) causes adverse cardiac
remodeling which is characterized with a variety of physiological, molecular, and cellular
alterations including cardiac cell death via necrosis and apoptosis, ER and oxidative
stress, inflammation, fibrosis, and hypertrophy (23). Previous studies have reported Doxinduced necrosis and apoptosis in cardiac cells (3; 28; 69); however, it is still unknown if
Dox induces an inflammatory-mediated form of cell death called “pyroptosis” in the heart.
This study was established to determine whether Dox is able to induce pyroptosis in
cardiac cells.
Treatment through transplantation of embryonic stem cell (ES cells) is known as a
potential approach in many diseases including cardiovascular disorders (CVDs) (50; 53);
however, the major restrictive challenge of this approach is teratoma formation due to
pluripotency of these undifferentiated stem cells (16; 38; 58). Recently, many experiments
have been focused to find a safer replacement to ES cell therapy that could be as efficient
as ES cell transplantation. Current studies have introduced administration of ES cellderived exosomes as a novel therapeutic strategy (21; 40; 51). Exosomes (Exos), 30-100
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nm diameter cell-derived vesicles, contain all parental cell contents, including proteins,
lipids, growth factors, and micro-RNAs (miRNAs), that are released from cell through
exocytosis (5; 12). According to current experiments, exosomes-derived from ES cells
are expected to be as effective as ES cells in cardiac protection and repair, and also,
these cell-free carriers are able to relieve the major challenge of ES cells, tumor formation
(51; 56; 67). We designed this study because there is currently no evidence that supports
the potential properties of ES-Exos on inhibition of Doxorubicin-induced pyroptosis in
cardiac cells.
For this purpose, we developed an in vitro experiment in which H9c2 rat
cardiomyoblasts were exposed to Dox to induce pyroptosis and then treated these cells
with ES-Exos to determine the therapeutic potential. MEF-derived Exos were used as
negative control. Our data demonstrates significant enhancement in pyroptotic cell death
and inflammation upon Dox administration; while, ES-Exos dramatically inhibited
pyroptosis and inflammation in these H9c2 cells.

9

Methods and Materials
Exosome Isolation

ES cells (mouse CGR8 cell line) and the MEF cell line were obtained from
American Type Culture Collection (ATCC, USA) and cultured as previously described
(62). In brief, ES cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 15% ES-fetal bovine serum (ES-FBS), leukemia inhibitory factor (LIF),
glutamine, penicillin/streptomycin (P/S), sodium pyruvate (NaP), and β-mercaptoethanol.
MEF cells were cultured in differentiation medium (DM) containing DMEM, 10% FBS,
glutamine, NaP and P/S. After 48 hours, the medium was replaced with serum free
knockout (KO) DMEM supplemented with glutamine and P/S. After 48 hours, exosomes
were isolated from ES and MEF cell culture medium (KO DMEM) using Exoquick-TC
exosome isolation kit (SBI) according to commercial manufacturer instruction.

H9c2 Cell Culture Model

H9c2 cardiomyoblasts, isolated from rat heart, were purchased from ATCC and
maintained in DM in 100 mm tissue culture plates and 8 well slides for 48 hours. Cells
were assigned to four different study groups: Control (cells in DM), Dox (2 µM
concentration, 24 hours incubation), Dox+ ES-Exos (in addition to Dox, 10 µg conc. of
Exos for 24 hours), and Dox+ MEF-Exos (in addition to Dox, 10 µg conc. of Exos for 24
hours; used as a negative control).
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Immunocytochemistry Staining (ICC)
H9c2 cells were fixed with 4% paraformaldehyde (PFA, Fisher Scientific) for 15
minutes and 0.3% Triton X-100 (Fisher Scientific) for 15 minutes prior to blocking with 10
percent normal goat serum (Vector Lab). After incubation with primary antibodies for:
TLR-4 (1:100 dilution; Abcam), NLRP3 (1:80; LSBio), caspase-1 (1:100; Abcam), and IL1β (1:100; Abcam) overnight at 4C, cells were exposed to the secondary antibody, Alexa
568 goat anti-rabbit (1:50; Invitrogen) for one hour at room temperature (RT) and then
DAPI (4,6-diamino-2-phenylindole) (Vector Lab) was applied to stain nuclei. Finally,
coverslips (Fisher) were mounted on the slides. Images for quantification were taken
using Olympus fluorescent (Center Valley, PA, USA) and Leica confocal (Buffalo Grove,
IL, USA) microscopes. The percentage of pyroptotic cell death was calculated by dividing
the total positive cells over the total DAPI, multiplied by 100 (total cells+ve/total
DAPI)*100. Graphs were created using ImageJ and Sigma Plot softwares.
SDS-PAGE and Western Blot Analysis
Western blot was performed as previously reported (33). In brief, H9c2 cells were
lysed using RIPA (radio-immunoprecipitation assay) cell lysis buffer, cell lysate
supernatant collected and estimation of protein concentration was performed using the
Bio-Rad assay, where the concentration was read at 595 nm by the plate reader. 70 µg
of proteins were loaded in 10% or 15% SDS gel (running at 150 V for 60-90 minutes),
gels were transferred to PVDF (Bio-Rad) membranes using transfer buffer and a semidry transfer machine (Bio-Rad). The membranes were blocked with 5% skim milk and
incubated with primary antibodies for TLR-4, NLRP3, caspase-1, IL-1, caspase-11,
11

gasdermin-D, TNF-α, IL-6 (1:1000; Abcam), and β-actin (1:1000, Cell Signaling, loading
control) overnight at 4C. Following washing the membranes with 1XTBS-T buffer,
membranes were incubated with HRP-conjugated goat anti-rabbit secondary antibody
(1:1000, Cell Signaling) for one hour. Following exposure with chemiluminescence ECL
substrates (Fisher Scientific), membranes were developed on x-ray film. Intensity
quantification of western blot bands was completed using ImageJ, and graphs were
created using Sigma Stat and Sigma Plot (band intensity quantities were shown as
arbitrary units (A.U.)).
Enzyme-Linked Immunosorbent Assay (ELISA)
Inflammation was also measured using mouse ELISA kits for TNF-α and IL-6
cytokines (Ray Biotech) using manufacturer’s instruction. In brief, diluted supernatant was
incubated in pre-coated wells for 2 hours at RT. Following washing wells with 1X wash
buffer, TNF-α, and IL-6 antibodies (1:80 dilution) were added to the wells for an hour at
RT. After primary antibodies were incubated, HRP-conjugated secondary antibody (1:200
dilution) was added in each well for 45 minutes. Finally, developing substrate and stop
solution were added to the wells, and plate was read at 450 nm by the plate reader. Raw
numbers were normalized with a standard curve and data were expressed as A.U.
Statistical Analysis
Data analysis via one-way analysis of variance (ANOVA) was followed by Tukey
test, and expressed as a mean ± SEM. P-value <0.05 was considered statistically
significant.
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Results
Treatment with ES Cell-Derived Exosomes Inhibits Dox-Induced Pyroptois in
H9c2 Cadiomyoblasts
To understand the protective effect of ES-Exos against pyroptotic cell death,
staining was performed using pyroptotic markers, TLR-4, NLRP3, caspase-1, and IL-1β.
Figures 2A, 2C, 4A, and 4C show representative staining images from all four study
groups in the DIC cell culture model. Quantitative analysis shows a significant increase
in TLR-4+ve (Fig.2B), NLRP3+ve (Fig.2D), caspase-1+ve (Fig.4B), and IL-1β+ve cells
(Fig.4D) in Dox group as compared to the control (p<0.05). Importantly, the percentage
of pyroptotic cell death dramatically decreased following treatment with ES-Exos vs. the
Dox group (p<0.05) (Fig.2 and 4). However, no significant changes occurred upon MEFExos administration vs. Dox treated cells (Fig. 2 and 4). To confirm the ICC results,
western blot was performed using the same pyroptotic markers: TLR-4, NLRP3, caspase1, and IL-1β. Densitometric measurement showed a significant augmentation in TLR-4
(Fig.3A), NLRP3 (Fig.3B), caspase-1 (Fig.5A) and IL-1β (Fig.5B) protein expression in
the Dox group vs. control (p<0.05); while, administration of ES-Exos reduced this
expression notably as compared to Dox (p<0.05). No significant changes were noted in
the MEF-Exos treated cells vs. Dox (Fig. 3 and 5).
Moreover, western blot analysis was performed for other pyroptotic markers,
caspase-11 and Gasdermin-D. Intensity quantification showed a significant increase in
caspase-11 (Fig.6A) and gasdermin-D (Fig.6B) expression in Dox compared to the
control (p<0.05); while, ES-Exos administration reduced this expression notably vs. Dox

13

(p<0.05). MEF-Exos did not make significant changes to these markers expression vs.
Dox (Fig.6).
Administration of ES-Exos Indicates a Significant Decrease in the Expression of
Pro-Inflammatory Cytokines, TNF-α and IL-6, in H9c2 Cell Culture Model of Dox
Induced Pyroptosis
To understand the protective outcome of ES-Exos against inflammation, western
blot and ELISA quantification were performed to analyze inflammatory cytokines TNF-α
and IL-6. According to our WB results, exposure to Dox enhances secretion of TNF-α
(Fig.7A) and IL-6 (Fig.7B) vs. control significantly (p<0.05); while, treatment with ESExos diminished this secretion notably as compared to Dox (p<0.05) (Fig.7). No
significant changes have been reported upon MEF-Exos treatment as compared with Dox
(Fig.7).
To verify WB data, ELISA was performed to quantify the secretion of these proinflammatory cytokines. Our data show that TNF-α (Fig.8A) and IL-6 (Fig.8B) expression
is significantly higher in the Dox group vs. the control (p<0.05); whereas, ES-Exos
decreased inflammation notably as compared with Dox (p<0.05) (Fig.8). MEF-Exos was
non-significant vs. Dox (Fig.8).
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Discussion
An equilibrium between cell survival and cell death is required to keep and improve
the tissue/organ homeostasis within the body (13; 30). Cell death is a biological
phenomenon (13); however, unwanted aberrant cell death can cause serious problems
and diseases. Two major categories of cell death that have been investigated previously
are apoptosis and necrosis. Apoptosis occurs via activation of cytochrome C and
apoptosome construction, which stimulates the caspase-3 cascade (9). Apoptosis is
characterized by membrane rupture, cell shrinkage, chromatin condensation, which lead
to breaking the DNA and the cell into apoptotic fragments. However, necrosis causes
swelling and disruption of cells through a loss of membrane integrity that is followed by
secretion of cellular contents into the environment, which promotes a strong inflammatory
response in the surrounding tissue (22; 25; 26; 46).
Furthermore, there is another type of programmed inflammatory-mediated cell
death known as pyroptosis. Pyroptosis happens via a series of events, including
activation of the TLR-4 receptor in response to DAMPs, which is followed by the
generation of NLRP3 inflammasome, induction of the caspase-1 cascade, and
downstream release of IL-1 and IL-18 cytokines. Stimulated caspase-1 also triggers
caspase-11 and gasdermin-D, which contribute to pore formation within the membrane
and pro-inflammatory cytokines secretion from dead cells (11; 18; 34; 42).
In this study, a DIC model of pyroptosis was generated using H9c2 cells. The
pyroptotic markers: TLR-4, NLRP3, caspase-1, IL-1, caspase-11, and gasdermin-D
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were examined via ICC and western blot analysis. To understand the protective role of
exosomes derived from ES cells, H9c2 cells were treated with ES-Exos. Quantitative
analysis of ICC and densitometric analysis of western blotting showed a notable increase
in pyroptotic markers in the Dox group vs. control; however, ES-Exos dramatically
decreased pyroptosis in comparison to the Dox treated cells. Additionally, proinflammatory cytokines secretion enhanced dramatically following Dox treatment vs.
control; while ES-Exos reduced inflammation significantly as compared to Dox exposed
H9c2 cells. This data suggests that ES-Exos are beneficial in that they are cell-free
carriers of therapeutic agents and are capable of bypassing the major side effect of
teratoma formation associated with ES cells (68).
Moreover, MEF-Exos were used as a control group in this experiment to establish
whether protection caused by ES-Exos in the Dox-induced pyroptosis model is cell
specific. According to our data, MEF-Exos administration did protect H9c2 cells exposed
to Dox from pyroptosis. This ineffectiveness might be due to various compositions of
miRNAs and growth factors found in MEF-Exos vs. ES-Exos. In addition, previous studies
support ES-Exos as cytoprotective agents (44; 62; 64), which is likely the reason for
protection from pyroptosis in this study.
In conclusion, the current study provides evidence that Dox induces pyroptosis and
inflammation in H9c2 cells, which can be inhibited upon treatment with ES-exosomes.
The significance of this novel study is the establishment of pyroptosis as a major
contributor in Dox induced cardiotoxicity. However, further elucidation is necessary to
determine the mechanism of pyroptotic development in DIC. Moreover, further studies
16

are needed to determine the specific factors and micro-RNAs responsible for inducing the
cytoprotective features demonstrated by ES-Exos in this Dox induced pyroptosis model.
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Figures

Figure 2. ES-Exos Treatment Diminishes Dox-Induced Pyroptosis in H9c2 Cells.
Representative images show a significant enhancement in TLR-4+ve (A) and NLRP3+ve
cells (C) in Dox vs. control; while, treating cells with ES-Exos decreased these pyroptotic
markers dramatically vs. Dox. No notable change has been reported in pyroptotic cell
death in the MEF-Exos group. Panels A and C show TLR-4 and NLRP3 positive cells in
red (a, d, g, j), DAPI in blue (b, e, h, k) and merged images (c, f, i, l). The histograms seen
in B and D indicate quantification of TLR-4+ve and NLRP3+ve cells over total DAPI. *p<0.05
vs. control, #p<0.05 vs. Dox, $p=NS (non-significant) vs. Dox, Scale bar = 100 µm, n=4.
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Figure 3. ES-Exos Downregulate TLR-4 and NLRP3 Expression in an In Vitro
Model of DIC.
WB densitometry revealed a significant increase in TLR-4 (A) and NLRP3 (B) pyroptotic
markers expression upon Dox exposure as compare to control; however, this expression
notably diminished following treatment with ES-Exos. No significant changes occurred in
MEF-Exos treated cells as compared with Dox. β-actin was used as a loading control.
Quantities represented as arbitrary unit (A.U.). *p<0.05 vs. control, #p<0.05 vs. Dox,
$p=NS vs. Dox, n=4.
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Figure 4. ES-Exos Inhibit Dox-Induced Pyroptosis in H9c2 Cells.
Representative photomicrographs taken using confocal microscopy indicate a meaningful
increase in the number of caspase-1+ve (A) and IL-1β+ve cells (C) in Dox vs. control. ESExos reduced caspase-1 and IL-1β secretion notably vs. Dox; while no significant
changes were observed in pyroptotic cell death upon MEF-Exos administration. Panels
A and C exhibit caspase-1 and IL-1β positive cells in red (a, d, g, j), DAPI in blue (b, e, h,
k) and merged images (c, f, i, l). The histograms in B and D indicate quantitative analysis
of caspase-1+ve and IL-1β+ve cells over DAPI. *p<0.05 vs. control, #p<0.05 vs. Dox, $p=NS
vs. Dox, Scale bar = 100 µm, n=4.
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Figure 5. ES-Exos Therapy Reduced Pyroptotic Markers, Caspase-1 and IL-1β, in
the DIC Cell Culture Model.
Intensity quantification of WB bands demonstrates that expression of caspase-1 (A) and
IL-1β (B) is drastically higher in Dox exposed cells vs. control; however, this secretion
decreased following treatment with ES-Exos when compared with Dox. No significant
changes appeared in MEF-Exos treated cells vs. Dox. We used β-actin as the loading
control. Quantities represented as A.U. *p<0.05 vs. control, #p<0.05 vs. Dox, $p=NS vs.
Dox, n=4.
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Figure 6. Treatment with ES-Exos Diminishes Pyroptotic Markers, Caspase-11 and
Gasdermin-D, in H9c2 Cells.
Figure 6 indicates a dramatic increase in caspase-11 (A) and gasdermin-D (B) expression
upon Dox administration vs. control; however, this enhanced level diminished after
treatment with ES-Exos as compared with Dox. No significant changes have been
reported in MEF-Exos treated cells in comparison to Dox. β-actin was used as the loading
control. Intensities denoted as A.U. *p<0.05 vs. control, #p<0.05 vs. Dox, $p=NS vs. Dox,
n=4-5.
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Figure 7. ES-Exos Decrease Secreted TNF-α and IL-6 Cytokines in H9c2 Cells
Following Dox Administration.
Densitometry quantification reports a notable increase in the expression of TNF-α (A) and
IL-6 (B) markers in Dox treated H9c2 cells vs. control; while, this expression has been
downregulated upon treatment with ES-Exos, notably. No significant change happens
regarding MEF-Exos treatment in comparison to Dox. Quantities signified as A.U. and βactin was used as the loading control *p<0.05 vs. control, #p<0.05 vs. Dox, $p=NS vs.
Dox, n=3-5.
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Figure 8. ES-Exos Therapy Reduces Inflammation upon Dox Administration in
H9c2 Cells.
Presence of TNF-α and IL-6 cytokines was quantified through ELISA. According to the
data, secretion of TNF-α (A) and IL-6 (B) was increased significantly upon Dox exposure
vs. control; whereas, ES-Exos diminished these inflammatory cytokines dramatically in
comparison to Dox. No significant changes observed in MEF-Exos group as compared
with Dox. *p<0.05 vs. control, #p<0.05 vs. Dox, $p=NS vs. Dox, n=5-7.
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CHAPTER 3: PROTECTIVE EFFECT OF ES CELL-DERIVED EXOSOMES ON
INHIBITION OF DOXORUBICIN-INDUCED PYROPTOSIS IN SOL 8 CELLS
Published at www.nrcresearchpress.com/cjpp on 19 September 2017 by Canadian
Journal of Physiology and Pharmacology. dx.doi.org/10.1139/cjpp-2017-0340.
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Abstract
Doxorubicin

is

used

as

an

antineoplastic

drug.

Unfortunately,

this

chemotherapeutic agent induces toxicity specifically in the heart and skeletal muscles due
to increased inflammation, as well as ER and oxidative stress. However, it remains
unknown whether Dox causes pyroptosis, a new form of inflammatory-mediated cell
death. In this study, we examined whether pyroptosis occurs upon Dox treatment in
mouse soleus muscle cells (Sol 8) in an in vitro model, and the protective effect of
exosomes isolated from embryonic stem cells (ES-Exos) against pyroptosis. For this
purpose, an in vitro model of muscle toxicity was generated using Sol 8 cells that were
exposed to Dox and inflammatory conditioned medium, and subsequently treated with
exosomes. Pyroptosis was verified through immunocytochemistry and western blot
analysis using pyroptotic markers caspase-1, IL1β, and IL-18. Our data illustrates a
notable upregulation in caspase-1, IL-1β, and IL-18 expression upon Dox exposure,
which was repressed through treatment with ES-Exos significantly. Treating cells with
MEF-Exos (a negative control) did not show any significant changes vs. Dox.
Furthermore, using the GW4869 compound (another negative control) in this study
resulted in inhibition of ES-Exos functional activity. This suggests that these derived
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vesicles from ES cells are the main key player to prevent or inhibit pyroptosis. The data
suggests that Dox induces inflammatory pyroptosis in Sol8 cells, which is mitigated by
ES-Exos treatment.

Introduction
Doxorubicin is used to treat numerous tumors and cancers through chemotherapy (35;
48). However, Dox application is limited due to acute dose-dependent heart and muscle
toxicities, which could result in cardiomyopathy, heart failure, muscle fatigue, and
dysfunction (6; 7; 37). Dox-induced muscle toxicity (DIMT) causes adverse remodeling
within muscle tissue, which has been characterized by cell death, fatigue, atrophy, and
fibrosis. This remodeling is usually due to inflammation, and oxidative/ER stress.
Doxorubicin stimulates inflammatory and metabolic changes in skeletal muscles (35);
however, further study is required to determine if Dox treatment results in pyroptosis in
soleus muscle cells. Thus, this study was designed to clarify whether Dox administration
and inflammation induce pyroptosis in skeletal muscle cells through developing a cell
culture model using Sol 8 cells, which were exposed to Dox and THP-1 conditioned
medium.
Previous studies support the great potential of stem cells to treat various disorders
including muscle diseases (32). However, treatment with ES cells increases the risk of
teratoma formation, which limits clinical application of this therapeutic approach.
Therefore, replacing cell-therapy with an alternative safer strategy should be considered.
Current studies indicate that released exosomes from ES cells could be considered as a
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replacement to ES cell transplantation (24; 41). Exosomes, 30-100nm diameter vesicles,
are secreted by the cell and contain all the cell’s components including proteins, growth
factors, lipids, and microRNAs (41). Moreover, it has been proposed that exosomes
derived from stem cells can posess all of the stem cell’s features and capabilities, such
as protection against apoptosis and fibrosis, in addition to neovascularization within the
heart and muscle tissues (24; 44; 45; 70). Currently, the protective effect of ES-Exos on
inhibition of Dox-induced pyroptotic cell death in Soleus muscle cells is unknown.
Therefore, we investigated the cytoprotectivity of ES-Exos on a Dox-induced pyroptosis
model that was established using Sol 8 cells. Furthermore, inflammatory conditioned
medium generated from THP-1 cells, a monocyte cell line, was used in this study to
generate more inflammation. We treated cells with Dox and THP-1 CM to induce
pyroptosis in Sol 8 cell culture model. This in vitro experiment simulates in vivo DIMT (20).
Our data indicates that ES-exosomes diminished pyroptosis within Sol 8 cells, and this
could be due to protective nature of miRNAs present in exosomes.
Methods and Materials
Preparation of THP-1 Conditioned Medium and Exosomes
To generate further inflammation within our cell culture model, we prepared
inflammatory conditioned medium (CM) from THP-1 cells (American Type Culture
Collection, USA), which was then added in addition to Dox. For TCM preparation, cells
were cultivated in suspension using Roswell Park Memorial Institute (RPMI) medium.
After 48 hours, the RPMI was collected, centrifuged, and the supernatant was filtered
(0.22 µl Millipore filter) and used as THP-1 CM. We purchased ES cells (mouse CGR8
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cells) and mouse embryonic fibroblasts from ATCC and cultured them as explained
previously (27; 54). To isolate exosomes, cell culture medium was replaced with knockout
DMEM (KO DMEM). Exosomes were isolated from KO DMEM using ExoQuick-TC
exosome isolation kit (SBI) using the manufacturer’s protocol. To support the
cytoprotectivity of ES-Exos, GW4869 compound, which acts as an exosome inhibitor,
was used in this experiment.
Generation of Muscle Cell Culture Model of Pyroptosis
Sol 8 cells (soleus muscle cells isolated from mice) were bought (ATCC, USA) and
maintained in DM (Differentiation Medium) containing Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 20% fetal bovine serum (FBS), glutamine, sodium
pyruvate (NaP), and penicillin-streptomycin. We assigned cells into 5 different groups
including: Control, Dox+THP-1CM, Dox+THP-1CM+ES-Exos, Dox+THP-1CM+MEFExos and Dox+THP-1CM+ES-Exos+Gw4869. To develop our study model, cells were
exposed to Dox (5µM) and THP-1 CM (30% volume/volume) for 4 hours. Following
changing culture medium with fresh medium, cells received different treatments such as:
ES-Exos (10 µg), MEF-Exos (10 µg; as a control) or ES-Exos+GW 4869 (10µM; to inhibit
ES-Exos function, used as another control) for 24 hours.
Immunocytochemical Staining
Pyroptosis was detected using immunocytochemistry. Thus, the Sol-8 cells grown
in 8 well culture slides were fixed with 4% PFA (20 minutes) and 0.3%Triton X-100 (15
minutes). Following blocking the cells with 10% normal goat serum (Vector Lab), cells
were incubated overnight with caspase-1 (Abcam, 1:100), IL-1β (Abcam, 1:100), and IL28

18 (Abcam, 1:100) antibodies at 4°C. Then, cells were exposed to Alexa 568 goat antirabbit secondary antibody (1:50 dilution, Invitrogen) for one hour at RT. Finally, mounting
medium containing DAPI (Vector Lab) was applied on the slides to stain nuclei and
coverslips (Fisher) were mounted. The pictures were taken using fluorescent and
confocal microscopy, and ImageJ software was used for quantitative analysis. The data
analysis and graph creation were performed using Sigma Plot.
SDS-PAGE and Western Blotting
SDS polyacrylamide gel electrophoresis was performed as published previously
(1). In brief, RIPA buffer was used to lyse the Sol 8 cells. This was followed with collection
of the supernatant and estimation of the protein concentration through the Bio-Rad protein
assay at 595 nm using a microplate reader (Bio-Rad). 60 µg of protein samples were
loaded in 10 % and 15 % SDS gels, and run for an hour. The gels were transferred onto
PVDF (polyvinylidene difluoride) membranes (Bio-Rad), and blocked with 5% skim milk.
Following blocking, membranes were incubated overnight at 4°C with primary antibodies
including: caspase-1 (Abcam, 1:1000), IL-1β (Abcam, 1:1000), and β-actin (Cell
Signaling, 1:1000, loading control). After incubation with HRP goat anti-rabbit secondary
antibody (Cell Signaling, 1:1000) for one hour at RT, the membranes were then exposed
to chemiluminescence ECL substrate reagents (ThermoFisher) for 2 minutes. Finally, the
membranes were developed on x-ray film. Densitometry quantification was completed
using ImageJ and graphs were created using Sigma Stat and Sigma Plot softwares
[intensities were quantified based on the loading control expression and denoted as
arbitrary unit (A.U.)].
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Statistical Analysis
Data were expressed as the mean ± SEM. P-value <0.05 denoted statistically
significance when assessed using one-way analysis of variance (ANOVA) and Tukey test.
Results and Discussion
Cell death is a natural incident, which is required for maintenance of the
organ/tissue inside the body. Apoptosis and necrosis, two major forms of cell death, would
occur in normal situation (to balance cell survival and proliferation), as well as in disease
conditions. Apoptosis is kind of planned cell death mediated through induction of the
caspase 9/3 cascade (25; 26). On the other hand, necrosis is a different form of cell
damage that results in secretion of inflammatory contents from the injured cell (25).
DAMPs, which are release in stress and inflammatory situations, have great potential for
activation of the TLR-4 receptor and the NLRP3 inflammasome. This inflammasome can
activate caspase-1 and stimulate secretion of pro-inflammatory cytokines including IL-1β
and IL-18 (4; 10; 61).
In this experiment, we developed a DIMT cell culture model using Sol 8 cells that
simulates in vivo muscle toxicity upon Dox treatment. (20; 57). Pyroptosis was examined
using pyroptotic markers caspase-1, IL-1β, and IL-18 via staining and western blot
analysis. Our results indicate that Dox and THP-1 CM significantly increased caspase1+ve (Fig. 9A and B), IL-1β+ve (Fig. 9C and D), and IL-18+ve cells (Fig. 9E and F), which
suggest pyroptosis is occuring in the muscle cells. (Fig.1 B and D). To further confirm the
ICC data, western blot evaluation was performed using IL-1β and caspase-1 antibodies
(Fig.10). Intensity quantification demonstrates a notable enhancement in caspase-1 and
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IL-1β expression following exposure to Dox+THP-1 CM in comparison to control group
(Fig.10). This experiment shows that inflammation generated by Dox and THP-1 CM
results in pyroptotic cell death in Sol 8 cell culture model. These data support the
involvement of pyroptosis in DIMT, which is consistent with some previous reports (4; 71).
Exosomes have been described as cytoprotective agents in several disease
conditions such as cardiac and skeletal muscle disorders (41; 44; 45). However,
additional examination is required to determine whether ES-Exos are protective against
pyroptosis in an in vitro model of DIMT. According to the current study’s data, treatment
with ES-Exos notably decreases the number of capase-1, IL-1β, and IL-18 positive cells
in comparison to Dox+THP-1 CM treated cells (Fig. 9). The immunocytochemistry results
were further corroborated with western blot analysis. WB densitometry revealed a
significant enhancement in caspase-1 and IL-1β expression in Dox+THP-1 CM group vs.
control; however, treating cells with ES-Exos dramatically reduced these markers as
compared to Dox+THP-1 CM (p<0.05). moreover, we treated Sol 8 cells with MEF-Exos
to understand whether protective effect observed with ES-Exos are cell specific, or if
exosomes secreted by other cells can also demonstrate protection against Dox-induced
pyroptosis in muscle cells. Our results show that administration of MEF-Exos has no
effect on pyroptosis in this culture model. This might be due to different miRNAs
compositions in MEF-Exos as compared to ES-Exos. These data also support previous
reports regarding ES-Exos cytoprotectivity (41; 64; 70).
The GW4869 compound serves to offset exosomes function (21). This compound
attenuates Exos activity through inhibition of the natural sphingomyelinase-2 enzyme,
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which involved in generation of lipid ceramide via hydrolysis of membrane lipid
sphingomyelin, and contribute to exosomes generation and uptake by the cells (59). In
the current experiment, we explored the effect of GW4869 on inhibition of ES-Exos
protective function in Dox-induced pyroptosis model through measuring caspase-1, IL1β, and IL-18 expression. Staining and WB data exhibited that pre-treatment with GW
compound blocked protective effects observed with ES-Exos in reduction of pyroptosis.
Therefore, treatment with ES-Exos+GW did not show significant changes in caspase-1,
IL-1β, and IL-18 expression as compared to Dox+THP-1 CM group (Fig. 9 and 10).
In summary, Dox and THP-1CM stimulate pyroptosis in soleus muscle cells (Sol
8); while, ES-Exos inhibit pyroptosis in these cells. The importance of this novel study is
the development of DIMT due to pyroptotic cell death; however, more investigation is
required to explain pyroptosis role in the progression of DIMT. Furthermore, additional
studies are needed to detect specific protective microRNAs in ES-Exos that are involved
in the cytoprotectivity of these vesicles.
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Figures

Figure 9. Administration of ES-Exos Inhibits Dox-Induced Pyroptosis in Sol 8
Cells.
Representative images show a notable enhancement in caspase-1+ve (A), IL-1β+ve (C),
and IL-18+ve (E) cells in the Dox+THP-1 CM group as compared to control. ES-Exo
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treatment reduced these markers significantly vs. Dox+TCM; while, no significant
changes happened with the addition of MEF-Exos or GW compound in comparison to
Dox+TCM. Panels A, C, and E show caspase-1, IL-1β and IL-18 positive cells in red (a,
d, g), DAPI in blue (b, e, h), and merged pictures (c, f, i). B, D, and F show created graphs
from quantitative results for caspase-1, IL-1β, and IL-18 positive cells over total DAPI.
*p<0.05 vs. control, #p<0.05 vs. Dox+TCM, $p=NS vs. Dox+TCM, Scale bar = 100 µm,
n=4.
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Figure 10. Protective Effect of ES-Exos on Reduction of Pyroptosis in DIMT
Model.
Figure 10 shows a dramatic increase in caspase-1 (A) and IL-β (B) expression upon Dox
and TCM exposure in Sol 8 cells; while, treating cells with ES-Exos reduced these
pyroptotic markers significantly vs. Dox+TCM. No significant changes reported in MEFExos and ES-Exos+GW groups vs. Dox+TCM. β-actin was used as the loading control
and intensities expressed as A.U. *p<0.05 vs. control, #p<0.05 vs. Dox+TCM, and $p=NS
vs. Dox+TCM, n=4-5.
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